Instituto de Investigación Sanitaria Fundación para la Investigación del Hospital Clínico de Valencia-ko ikertzaileekin lankidetzan egindako argitalpenak (31)

2024

  1. Alterations in the volume and shape of the basal ganglia and thalamus in schizophrenia with auditory hallucinations

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 131

  2. AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action

    Science advances, Vol. 10, Núm. 41, pp. eadn6525

  3. Early chronic fasudil treatment rescues hippocampal alterations in the Ts65Dn model for down syndrome

    Neurochemistry International, Vol. 174

  4. Mesenchymal Stem Cells Cultured in a 3D Microgel Environment Containing Platelet-Rich Plasma Significantly Modify Their Chondrogenesis-Related miRNA Expression

    International Journal of Molecular Sciences, Vol. 25, Núm. 2

  5. Msi2 enhances muscle dysfunction in a myotonic dystrophy type 1 mouse model

    Biomedical Journal, Vol. 47, Núm. 4

  6. Progressive loss of cortical gray matter in first episode psychosis patients with auditory hallucinations

    Schizophrenia Research, Vol. 267, pp. 534-545

  7. Taurine activates the AKT-mTOR axis to restore muscle mass and contractile strength in human 3D in vitro models of steroid myopathy

    Disease models & mechanisms, Vol. 17, Núm. 4

  8. The role of microRNAs in understanding sex-based differences in Alzheimer’s disease

    Biology of Sex Differences, Vol. 15, Núm. 1

  9. Therapeutic potential of oleic acid supplementation in myotonic dystrophy muscle cell models

    Biological Research, Vol. 57, Núm. 1

2023

  1. BlockmiR AONs as Site-Specific Therapeutic MBNL Modulation in Myotonic Dystrophy 2D and 3D Muscle Cells and HSALR Mice

    Pharmaceutics, Vol. 15, Núm. 4

  2. CRISPR-Cas9 editing of a TNPO3 mutation in a muscle cell model of limb-girdle muscular dystrophy type D2

    Molecular Therapy - Nucleic Acids, Vol. 31, pp. 324-338

  3. Fluoxetine increased adult neurogenesis is mediated by 5-HT3 receptor

    Neuroscience Letters, Vol. 795

  4. Natural Compound Boldine Lessens Myotonic Dystrophy Type 1 Phenotypes in DM1 Drosophila Models, Patient-Derived Cell Lines, and HSALR Mice

    International Journal of Molecular Sciences, Vol. 24, Núm. 12

  5. Neuroprotective properties of queen bee acid by autophagy induction

    Cell Biology and Toxicology, Vol. 39, Núm. 3, pp. 751-770

  6. Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression

    Molecular Therapy - Nucleic Acids, Vol. 34

  7. Quantitative magnetic resonance imaging assessment of muscle composition in myotonic dystrophy mice

    Scientific Reports, Vol. 13, Núm. 1

  8. The myotonic dystrophy type 1 drug development pipeline: 2022 edition

    Drug Discovery Today, Vol. 28, Núm. 3

  9. Volume alterations of the hippocampus and amygdala in patients with schizophrenia and persistent auditory hallucinations

    Revista de Psiquiatria y Salud Mental

2022

  1. Deciphering the Complex Molecular Pathogenesis of Myotonic Dystrophy Type 1 through Omics Studies

    International Journal of Molecular Sciences, Vol. 23, Núm. 3

  2. Development of potent tripodal G-quadruplex DNA binders and their efficient delivery to cancer cells by aptamer functionalised liposomes

    Organic and Biomolecular Chemistry, Vol. 21, Núm. 5, pp. 1000-1007